SCHEMBL2866057

SCHEMBL2866057

CN(C)Cc1ncccc1C(=O)NC(=S)Nc1ccc2c(c1)OC(c1ccccc1)O2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.41
RAB9A P51151 9/20 0.41
NPC1 O15118 8/20 0.41
MAPT P10636 8/20 0.41
SMN1; SMN2 Q16637 7/20 0.41
NFKB1 P19838 2/20 0.41
NFKB2 Q00653 2/20 0.41
RELA Q04206 2/20 0.41
ALOX12 P18054 5/20 0.40
HTT P42858 3/20 0.40
LMNA P02545 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SIRT2 Q8IXJ6 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14096269 0.85 ALDH1A1 (0.45) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2864605 0.82 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL3150330 0.81 RAB9A (0.44) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2869724 0.77 KDR (0.48) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2865599 0.76 ALDH1A1 (0.44) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2869492 0.76 ALDH1A1 (0.53) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2866075 0.75 MEN1 (0.56) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL13956804 0.75 ALDH1A1 (0.46) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL4366783 0.73 ALDH1A1 (0.44) ALDH1A1RAB9ANPC1MAPTSMN1; SMN2
SCHEMBL2873177 0.72 SIRT2 (0.56) ALDH1A1MAPTSMN1; SMN2HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US claimed
EP-1747196-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION Achillion Pharmaceuticals, Inc. (US) 2007-01-31 EP claimed
WO-2006083271-A2 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS, INC. (US) 2006-08-10 WO claimed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US claimed
US-7767706-B2 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2010-08-03 US disclosed
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US disclosed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication PIGS, NAT1, AADAC ALDH1A1 176/4885RAB9A 2277/4885NPC1 179/4885
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION PIGS, NAT1, AADAC ALDH1A1 176/4885RAB9A 2277/4885NPC1 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.